Bosutinib, Blood Cancer Therapy, Safe and May Help Some With ALS
Bosutinib, an inhibitor approved to treat a blood cancer, showed no unexpected safety concerns in people with amyotrophic lateral…
Articles by Marisa Wexler, MS
CRISPR/Cas9 Gene Editing Used to ‘Cut Out’ ALS Mutation: Early Study
A CRISPR/Cas9 gene editing system can be used to remove the repeat expansion in the C9ORF72 gene, the most common…
Top 10 ALS Stories of 2022
ALS News Today brought consistent coverage of the latest research developments and advances in treatment related to amyotrophic…
New Deal Helps Move Gene Therapy ET-101 Closer to Clinical Testing
Eikonoklastes Therapeutics and Forge Biologics have announced a new partnership to advance the development of ET-101, an experimental…
Analyses Support Design of COURAGE-ALS Trial of ReldesemtivÂ
The COURAGE-ALS Phase 3 clinical trial, testing Cytokinetic’s experimental therapy reldesemtiv in people with amyotrophic lateral sclerosis (ALS), is expected…
Effector T-cell Levels May Predict Disease Progression, Survival
Higher levels of inflammatory immune cells called effector T-cells at the time of diagnosis are associated with faster disease progression…
Tofersen to Treat SOD1 ALS Under Review for European Union
The European Medicines Agency (EMA) has agreed to review an application seeking the approval of tofersen in treating amyotrophic…
Implantable Device That Stimulates Muscles Prevents Atrophy in Mice
A soft robotic implantable device that can exert mechanical force on muscles was shown to reduce muscle atrophy in a…
Results of Phase 3 Trial of TUDCA in Slowing ALS Likely Next Year
An ongoing Phase 3 clinical trial in Europe is testing whether tauroursodeoxycholic acid, added to standard therapy, can slow disease…
ALS Patients Given NurOwn Calling for FDA Meeting to Discuss Refusal
People who took part in clinical testing of NurOwn, a cell therapy for amyotrophic lateral sclerosis (ALS), and family members…